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This is a report on some of the research activities currently ongoing in Italy as outlined at the “Viruses and solid
tumors” meeting jointly organized by the Oncology Sections of IRCCS Policlinico “San Matteo” (Pavia) and IRCCS
National Cancer Institute (Aviano), held in Pavia, Italy, on October 2011. Experts from the various disciplines involved
in the study of the complex relationships between solid tumors and viruses met to discuss recent developments in
the field and to report their personal contributions to the specified topics. Secondary end point was to establish a
multidisciplinary work group specifically devoted to solid tumors and infectious agents, aimed to identify areas of
common interest, promoting and establishing collaborative projects and programs, and to coordinate clinical and
research activities. The group, which will be named IVOG (Italian Viral Oncology Group), will operate under the
patronage of the various scientific societies of interest.Of viruses and tumors, general aspects
The first introductory lecture dealt with the fundamental
milestones of the long lasting and successful research on
viruses and cancer, such as the discovery of transforming
non-filterable agents that cause cancer, the identification
of the first human tumor virus (EBV), the discoveries
of proto-oncogenes (SRC) and tumor suppressor genes
(p53, Rb), and the first vaccination achievements (HBV,
HPV) (Umberto Veronesi, Istituto Europeo di Oncologia,
Milan, Italy). Then it was the turn to address the intimate
mechanisms of direct and indirect virus oncogenesis, il-
lustrating the key steps and complex regulatory circuits
that contribute to the cancer development (Giorgio Palù,
University of Padova, Italy). At the end, Antonino Carbone
(National Cancer Institute, Aviano, Italy) reviewed the mo-
lecular techniques for pathologic and virologic investi-
gations, including DNA/RNA detection techniques and
conventional immunohistochemistry for EBV, KSHV,
MCPyV and HPV.
Epidemiology
Epidemiology of virus-associated cancers was introduced
by Diego Serraino (IRCCS Centro di Riferimento Onco-
logico, Aviano, Italy) who presented an interesting study* Correspondence: v.perfetti@smatteo.pv.it
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reproduction in any medium, provided the oron HLA-A and -B high-resolution profile in EBV-asso-
ciated undifferentiated nasopharyngeal carcinoma (UNPC)
in Italy, a non endemic area for this disorder [1]; it was
shown that affected individuals present distinct HLA- gen-
etic profile, with significant hyper- and under-representa-
tion of specific alleles, compared to bone marrow donors.
As for other virus-driven tumors, the lack of an HLA
background favoring an efficient immune control of EBV-
infected cells may increase the risk to develop nasopharyn-
geal carcinoma, with data that are relevant for immuno-
therapy (EBV specific CTLs and vaccines) in these areas.
The estimated total number of cancer cases attribu-
table to infection in the year 2002 was 1.9 million, or
17.8% of the global cancer burden [2]. The attributed
fraction at the specific sites varied from 100% of cervical
cancers attributed to the papilloma viruses to a tiny pro-
portion (0.4%) of liver cancers (worldwide) caused by
liver flukes. Analysis of a number of cancer cases attri-
buted to infection by age group indicated that in deve-
loping countries virus-associated cancers cluster in the
50–69 age group. Silvia Franceschi, the epidemiologist
director of the Infection and Cancer Epidemiology Group
at the WHO/OMS International Agency for Research on
Cancer (IARC, Lyon, France), focused the attention on
HPV as a good example of a carcinogenic infection with
the typical features of an etiological association between
infections and human cancers. Data from the IARC Preva-
lence Surveys, 1990–2011, indicated that the prevalenceLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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presented a recent meta-analysis of HPV type-specific
prevalence data published from 1990 to 2010, inclu-
ding a total of 243 studies and 30,848 invasive cervical
cancers (ICC) [3]. Results showed that the proportion
of ICC associated with HPV-16 and HPV-18 was bet-
ween 70 and 76% in all world regions except for Asia.
The 12 most common HPV types identified, in order
of decreasing prevalence, were HPV-16 (57%), 18
(16%), 58, 33, 45, 31, 52, 35, 59, 39, 51 and 56. The
prevalence of other types, phylogenetically related to
those above, ranged from <0.1% for HPV 85 to 0.6%
for HPV-68. There was a significant increase in the
prevalence of multiple infections (from 4.0%, year
1990, to 15.7%, year 2010) and of HPV-16 (from 51.8
to 60.0%). Smaller, but relevant increases were also
seen for HPV-39, 53 and 58. According to recent
data, the fraction of anus cancer attributable to HPV
infection raised to 88%.
In recent studies the involvement of HPV infection in
head and neck cancers was investigated. Data indicated
that the fraction of oropharynx, tonsils and base of
tongue cancers attributed to HPV was 50% in developed
countries and 5% in developing countries (where smoke
and alcohol were the major risk factors). The natural
history of cervical HPV infection is well studied, whereas
the extension of cervical findings to HPV carcinogenesis
in the tonsil needs more investigations. Cervical HPV in-
fection is mainly transmitted through sexual intercourse,
and is very common and rising in all world population.
On the other hand, information on the prevalence and
the age at first acquisition of HPV infection to the
oropharynx is limited in quantity and quality. HPV-16
was found in 50% of cervical carcinoma and in 90%
of HPV-positive carcinomas of the oropharynx. The
precancerous HPV-associated lesions that precede cer-
vical carcinoma (CIN1-3) are well defined and widely
employed in screening programs. In contrast, precan-
cerous lesions in the oropharynx are poorly unders-
tood and not consistently classified. Contrary to cervical
carcinoma, very strong risk factors, other than HPV,
exist for oropharyngeal carcinoma (mainly smoke and
alcohol). In conclusion, Franceschi presented the fu-
ture objectives emerged from the FP-7 funded IARC
Study of human Papillomavirus and precancerous
Lesions In the Tonsil (SPLIT study): i) prevalence of
HPV infection in cancer-free tonsils and age at acqui-
sition; ii) detection of precancerous lesions in the
tonsil using histological and cytological examinations;
iii) differences between HPV-related precancerous
lesions in the oropharynx and those caused by other
risk factors (smoke, alcohol); iiii) fraction of oropha-
ryngeal carcinomas truly attributable to HPV, in dif-
ferent countries.Cancers related to HPV and hepatitis viruses (HBV
and HCV)
Head and neck (HN) cancers
HPV 16, and secondarily HPV 18, are by far the most
relevant human Papillomavirus types involved in oro-
pharyngeal, laryngeal and oral cavity cancer, being ob-
served in a relevant fraction of HN cancers, particularly
in oropharyngeal tract. A role cannot be excluded for
HPV types 6 and 11 too, since a minority of cancers (less
than 5-10%) can be demonstrated to harbor sequences
from these types. Several studies reported that detection
of HPV DNA is associated with poorly differentiated
cancer grade, positive lymph nodes, and late-stage dis-
ease, which traditionally indicate poor prognosis. Despite
these observations, the outcome of HPV-positive tu-
mors, progression-free survival (PFS) and overall sur-
vival (OS), appears to be significantly better than HPV
negative tumors [4]. The more favorable prognosis of
HPV-tumors was confirmed by a study conducted at the
National Cancer Institute of Milan [5], based on a retro-
spective series of 90 consecutive oropharyngeal cancer
patients treated primarily with surgery. Results showed
that HPV-positive status (19/90, all positive for HPV-16
genotype) was associated with improved overall survival,
reduced incidence of tumor relapse and second tumors.
The reasons for the more favorable prognosis of HPV-
positive tumors remain unknown; there are some bio-
logical elements typical of these tumors, such as lower
mutational rate and less complex chromosomal abnor-
malities, which may help to understand this issue. The
less complex genomic alterations may indicate that HPV
tumors are at an earlier step in the cancerogenesis evo-
lution, “younger” in comparison with their HPV-negative
counterparts, and therefore more easily treated and
characterized by lower recurrence rates. Marco Merlano
(A.O. Santa Croce e Carle, Cuneo, Italy) stated that there
is now sufficient evidence to consider determination of
HPV status mandatory in HN cancers, given its major
relevance as prognostic and predictive marker.
Overexpression of p16, a cell cycle regulator, in HPV-
positive oropharyngeal squamous cell carcinoma results
from degradation of pRb by the viral oncoprotein E7;
for this reason, p16 positivity at immunohistochemistry
has been proposed as a surrogate marker for high-risk
HPV infection. However, although some studies indi-
cated a good correspondence between p16 and HPV sta-
tus (assessed by DNA-ISH or mRNA E6/E7 Real- time
PCR), a recent study from the Licitra group in Milan [6],
evaluating an algorithm for the definition of HPV status
in oropharyngeal cancer, demonstrated the existence of a
cancer subset characterized by p16-positivity and con-
sistently negative HPV-ISH. These data clearly indicate
that evaluation of HPV via molecular biology is presently
necessary.
Perfetti et al. Infectious Agents and Cancer 2012, 7:23 Page 3 of 8
http://www.infectagentscancer.com/content/7/1/23Cervical cancer
The WHO/ICO 2010 summary report on HPV and Cer-
vical Cancer (HPV Information Centre) indicated 2880
new cervical cancer cases/year in Italy, with a crude inci-
dence rate of about 9.4 per 100,000 women/year, and
with a prevalence of HPV-16 and/or HPV-18 among wo-
men with high grade cervical lesions (HSIL, CIN2, CIN3
and CIS) of 55.7%, and with cervical cancer of 72.1%.
The crude incidence rate observed in Italy (9.4 per
100,000 women/year) indicated a slightly lower inci-
dence in comparison to other Southern Europe countries
(11.1%), but significantly lower compared to the global
overall incidence (15.8%). Arsenio Spinillo (University of
Pavia-Fondazione IRCCS Policlinico “San Matteo”, Pavia,
Italy) presented studies on multiple HPV strain infection
in cervical specimens. HPV DNA was investigated by
means of a robust and sensitive PCR method for the si-
multaneous detection of multiple HPV types (SFP10-LIPA,
detecting 15 high-risk and 10 low-risk HPV types) on a
consecutive series of 1323 women undergoing colposcopy,
69% of whom had a cervical biopsy, and correlated CIN
severity with the type and number of HPV [7]. The preva-
lence of HPV DNA was 97.3% in CIN 1 and 98.1% in
CIN≥ 2. Infection by multiple HPV types was observed in
the majority of cases (75%). The frequency of multiple
viral type detection increased in high-grade lesions (63.1%
CIN1 and 80.8% CIN≥ 2), with HPV-16 present, together
with other types, in approximately half of the cases.
Twenty-three different types were detected, HPV-16, 31,
51 being the most frequent. Number of viral types and
class of oncogenic risk were linearly correlated with CIN
severity by univariate and multivariate analyses. In this
Italian series, multiple infection per se was associated with
high-grade lesions, independently of HPV-16, stressing
the need to study the role of this phenomenon in cervical
precancerous lesions.
To study the distribution of HPV types in Northern
Italy over the years 1985–2007, the Pavia group validated
the SPF10 LiPA HPV typing assay in archival formalin
fixed paraffin embedded tissue [8]. Results showed im-
portant changes over the last decade, with a reduction of
the frequency of HPV 16/ 18 (HPV-16 decreased from
72 to 59%). Features of present infections were multiple
genotype infections (up to 60% in high-grade lesions)
and new HPV types (HPV-51, 52, 53, 56, 58, 66). The
prevalence of these emerging genotypes was distributed
over a wide range (5.7-30.8%) [9]. HPV-16 was the com-
monest genotype both in single and multiple infections.
Giorgio Palù presented preliminary data from his group
on miRNAs expression in HPV associated cervical cancer.
miRNAs are a new class of molecules recently studied
for their possible role in oncogenesis and cancer progres-
sion. Indeed, miRNAs expression is significantly altered
in many cancers, including cervical cancer. By miRNAsmicroarray and real-time PCR assays, Palù and collabora-
tors identified cellular miRNAs significantly associated
with HPV-16 E6 and E7 expression in human foreskin
fibroblasts and keratinocytes. The relevant miRNAs ap-
peared to be involved in the induction of cell proliferation,
cell differentiation, invasiveness, apoptosis suppression
and inhibition of IFN response; some of these miRNAs
were up-regulated, while others were down-regulated.
Successively, miRNAs expression was investigated in cer-
vical specimens of 120 subjects enrolled for cervical
cancer screening. Results demonstrated that these same
miRNAs were up-regulated or down-regulated also in vivo
and not only in vitro, attesting the relevance of this on-
going research.
HCC
HCC is the 5th most common cancer in men and 7th
one in women, and is the most frequent cause of death
in patients with HCV-related cirrhosis in developing
countries. Other risk factors for HCC are chronic HBV
infection and co-infections HBV/HCV, HIV/HCV and
HBV/HDV. In the first contribution on HCC, Mario
Mondelli (University of Pavia-Fondazione IRCCS Policli-
nico “San Matteo”, Pavia, Italy), described the viral and
cellular oncogenic pathways involved in the development
of HCC, focusing on the importance of surveillance that
might allow an early diagnosis of HCC in patients with
defined risks and consequently reduced mortality. Anti-
viral treatment can reduce, but not eliminate, the risk of
HCC in HBV/HCV infections. A 17 year prospective co-
hort study coordinated in Pavia [10] has demonstrated
conclusively that HCV genotype 1b was associated with
a significant higher risk of developing HCC.
In the other contribution Camillo Porta (Fondazione
IRCCS Policlinico “San Matteo”, Pavia, Italy) illustrated
the molecular pathogenesis of HCC by showing the
most relevant pathways, focusing on angiogenesis and
the mechanisms of deregulation of proliferation and
survival. Several molecularly target therapies are now
available, capable of interfering with these pathways
at various levels, including sunitinib, bevacizumab, erlo-
tinib, gefitinib and cetuximab, and promising new drugs
such as everolimus, and the Met inhibitor ARQ-187. Pre-
sently sorafenib, an oral inhibitor of the serine/threonine
kinase Raf-1 and of several tyrosine kinases involved in
angiogenesis (VEGFR2-3), is the only approved drug. A
multicenter study [11], with a relevant Italian contribu-
tion, showed that sorafenib prolonged median survival
and the time to progression by 3 months in patients with
advanced HCC. An important observation [12] is that
sorafenib was particularly active in HCV infected patients,
while decreasing HCV viral load.
As previously discussed for cervical cancer, miRNAs
may be involved in hepatocellular carcinoma as well.
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tion with the degree of fibrosis, in 40 chronic hepatitis/
cirrhosis patients. Results showed that some miRNAs
were up-regulated, whereas other miRNAs appeared
down-regulated. Relevant miRNAs had several targets
that were involved in some biological pathways that
promote collagene synthesis, cell proliferation, migration,
and epithelial to mesenchimal transition, suggesting a role
in viral hepatitis/cirrhosis progression. In a second set of
experiments, miRNAs expression was evaluated in 18
HCC patients. Results showed that some of the miRNAs
deregulated in advanced grade fibrosis were deregulated
in HCC too, suggesting a link between fibrosis and cancer.
Future studies will address the role of miRNAs as prog-
nostic indicators or diagnostic markers for HCC.
Other solid tumors with possible viral
pathogenesis, including Merkel cell carcinoma,
colorectal cancer, mesothelioma and brain tumors
The first speaker, Mauro Tognon (University of Ferrara,
Italy), focused the attention on personal data on polyo-
maviruses, brain tumors and Merkel cell carcinoma. SV40,
a potent transforming polyomavirus, was introduced in
the human population about 50 years ago by contami-
nated polio vaccines, since then its role in the patho-
genesis of human brain tumors, mesothelioma and colon
cancer has been periodically claimed. SV40 Tag-coding
sequences were found in various histotypes of human
brain tumors, including 83% of choroid plexus papillomas,
73% of ependymomas, 47% of astrocytomas and 33% of
glioblastomas [13,14]. Expression of SV40 early region
RNA was also investigated, and 78% of glioblastoma mul-
tiforme cell lines positive for SV40 DNA were found also
to express SV40 early region sequences. The numbers of
viral DNA copies detected by quantitative PCR were very
small, with an estimate of 1 copy per 100 cells.
Merkel cell carcinoma is a rare aggressive human skin
cancer, with a high mortality rate and an increasing inci-
dence, which is found prevalently in immunocompro-
mised hosts, such as transplant recipients, HIV patients,
and subjects with chronic lymphocytic leukemia. Recently,
sequences from a new polyomavirus, named Merkel poly-
omavirus (MCPyV), were found integrated in the genome
of a high proportion of Merkel cell carcinoma primary
samples. Clonal integration and the deletions and/or mu-
tations observed in the T antigen gene have suggested a
direct oncogenic role for MCPyV [15,16]. Tognon pre-
sented two collaborative studies aimed to test MCPyV
seroprevalence in a general European population and in
patients with Merkel cell carcinoma [17,18]. MCPyV vi-
ruslike particles (VLPs) were produced in baculovirus cells
and these were used to set up an ELISA test for identifica-
tion and quantification of serum antibodies to MCPyV.
MCPyV antibodies were detected in 100% of patients withMerkel cell carcinoma, and in approximately 85% of con-
trols [18]. Similarly to SV40, the new polyomavirus was
detected in buffy coats from healthy blood donors [19],
with a prevalence of 22%, indicating that exposure to
MCPyV is very common.
The session proceeded with a contribution on meso-
thelioma and gastrointestinal cancers. Manola Comar
(University of Trieste, Italy) discussed the SV40 role in
the pathogenesis of mesothelioma, as a possible cofactor
in the cancerogenetic process. Northeastern Italy may be
considered an hyperendemic area for mesothelioma, in
association with a massive occupational exposure to as-
bestos. In a first retrospective Italian study aimed to in-
vestigate the presence of SV40 in malignant and normal
tissues from mesothelioma patients of this area, Comar
and collaborators [20] detected SV40 DNA in approxi-
mately 3/19 tumors (15.8%, all positive for asbestos ex-
posure), 3/18 liver and 1/8 of kidney tissues from the
same patients. SV40 viral loads were higher in meso-
thelioma than in normal tissues. These results showed
for the first time that SV40 sustained infections in mul-
tiple tissues in malignant mesothelioma patients. The as-
sociation of SV40 with asbestos exposure was confirmed
in a larger study based on 63 cases of incident malignant
mesothelioma (Comar et al., unpublished observations).
These results suggest further investigation to clarify the
role of SV40 in the asbestos-dependent transformation
process.
Because of localization, providing exposure to external
environment, colon cancer may be a target for viral on-
cogenesis, and this is area of active investigation. Comar
presented two studies on polyomaviruses and colon can-
cer. In the first case–control study [21], DNA from fresh
biopsies from 94 cancer patients and 91 control subjects
were investigated for SV40, JCV and BK sequences. No
DNA from JCV and BK were detected either in patients
or controls. SV40 large T antigen fragments were found
in colon cancer tissues with a prevalence of 6.4%. The
second case–control study [22] was conducted on 64
cases of colon cancer and focused on the recently dis-
covered polyomavirus, MCPyV. Viral sequences were
detected with a similarly low prevalence, with no diffe-
rence between cases and controls (6.3% and 8.8%, res-
pectively). In either study, blood samples were negative.
Collectively, these studies demonstrate the existence
of SV40 and MCPyV sequences, but no JCV and BK,
with low prevalence rates in tumor tissues from colon
carcinoma.
EBV has an important role in the pathogenesis of
some solid tumors too, namely EBV-related nasopharin-
geal carcinoma and a variant of gastric cancer, compri-
sing approximately 15% of all gastric cancers. In his
talk on EBV-related solid cancers and relative immuno-
therapy approaches, Fausto Baldanti (Fondazione IRCCS
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resting case of EBV-Smooth Muscle Tumor (SMT) in
the context of kidney transplantation successfully treated
by minimizing immunosuppression [23], providing the
proof of principle that tapering immunosuppression is
feasible, successful and safe in patients with non aggres-
sive EBV-SMT. Active front-line therapies, such as the
infusion of EBV-specific T cells, antiviral therapies and
surgical excision, should be reserved for clinically aggres-
sive tumors or patients at high risk of acute and chronic
allograft rejection.
In an Italian retrospective study [24] on post-transplan-
tation proliferative disorders (PTLD) and EBV DNAemia
in a cohort of 137 patients receiving lung transplantation,
a similar case of EBV-related leiomyosarcoma occurred.
In this instance, autologous EBV-specific CTL were used
to induce remission of the tumor, giving proof that cell
therapy approaches are potentially active in the context of
EBV-related solid tumors as well.
Prevention and therapy
Franco Buonaguro (National Cancer Institute, IRCCS
Fondazione “G. Pascale”, Napoli, Italy) introduced the
section summarizing features of HPV virus replication,
transmission, and immune response. Then the speaker fo-
cused the attention on HPV vaccines. Target of preventive
vaccines is neutralization of virus before infection of basal
keratinocytes. Actual vaccines are based on recombinant
L1 protein, a major capsid protein, which is characterized
by self assembly to form virus-like particles in vitro.
Quadrivalent HPV (type 6, 11, 16, 18, from MERCK) and
bivalent HPV (type 16, 18, from GSK) L1 VLP vaccines
are available, and their efficacy was demonstrated in phase
III trials. Results from a phase II randomised placebo con-
trolled trials of a quadrivalent HPV [25] and bivalent HPV
L1 VLP vaccines [26] demonstrated efficacy in prevention
of incident and persistent cervical infections with HPV-16
and HPV-18, and associated cytological abnormalities and
lesions. Protection appears to last for 4–5 years. In a IARC
Working Group meta-analysis [27] HPV-16, 18, 45, 31,
33, 35, 52, 58 were the most common HPV types found in
invasive cervical cancer. The risk classification of the dif-
ferent HPV types is important for screening and vaccine
development, and it’s an open debate, since the oncogenic
potential of many virus types is yet to be defined. Another
open issue that may have a great impact on the virus
transmission to women is HPV vaccination of men, given
the role of carrier. To test for the prevalence of HPV in-
fection in immunocompromised patients in Italy, the pre-
sence of HPV infection was investigated in urine samples
of 88 male patients with renal transplants [28]. The
results showed that 48.9% of the samples were posi-
tive for HPV sequences, with high prevalence of HPV-
16 (53.5%). These results suggested that HPV-16 basedpreventive or therapeutic vaccine may be effective for
prevention and treatment of HPV-related neoplasia in
this group of immunocompromised patients.
As regards new HPV vaccines technologies, research is
focused on the production of capsomers and in low-cost
synthesis. Vaccine production in other systems, such as
in plants will permit safer and cheaper synthesis of viral
molecules for the developing world. The author is ac-
tively pursuing vaccine development in tobacco plants.
Therapeutic vaccines are also under development, spe-
cifically based on several long peptides derived from
proteins E6 and E7. While these strategies have proven
to be successful in animal models of HPV neoplasia
(mice and rabbits), ways to improve the T helper 1 re-
sponse are being investigated, including the use of den-
dritic cells exposed to viral peptides ex vivo.
The role of antiviral therapy in HCC prevention was
introduced by Raffaele Bruno (Fondazione IRCCS Poli-
clinico “San Matteo”, Pavia, Italy) who presented a col-
laborative retrospective study of the Italian Association
for the Study of the Liver (AISL) [29] on the impact of
sustained virological response (SVR) on the long-term
outcome of 848 patients with HCV-related cirrhosis
treated with IFNα. The results showed that the patients
with SVR had a lower risk of liver-related complications
and a reduction in liver-related mortality. Another
prospective study from Bruno et al. [30] conducted on
352 patients with compensated HCV-induced cirrhosis,
confirmed that the achievement of SVR was associated
with a reduction of decompensation rate and mortality.
These studies also showed that patients with SVR had a
lower risk of HCC development. A further study [31]
investigated the impact of antiviral therapy in decom-
pensated HCV-related cirrhotic patients. The results
showed that the achievement of a SVR in these patients
reduced disease progression and may be life-saving.
However, SVR rates were significantly lower in patients
with advanced fibrosis [32]. SVR rate is also associated
with viral genotype. SVR is higher in genotype 2
patients, and so these patients have an advantage in the
treatment response [33].
Cell-based immunotherapy against virus-mediated can-
cers was discussed by Patrizia Comoli (Fondazione IRCCS
Policlinico “San Matteo”, Pavia, Italy). The investigator
illustrated the last 15 years experience on cell therapy
for EBV-related PTLD in immunocompromised patients
[34]. Cell therapy was based on generation of EBV-specific
CTLs that were used in their experience after preemptive
rituximab failure. In high-risk cohorts, such as haplo-
HSCT recipients, infusion of donor EBV-specific CTLs
contributed to a significant improvement of outcome [35],
and induced viral DNA clearance and remission of PTLD
in all treated patients [36]. More recently this cell the-
rapy was applied to EBV-related solid tumors, such as
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subset of patients that relapsed after chemo-radiotherapy
treatment. Data from the first study conducted [37]
showed that successful autologous cell therapy was typic-
ally observed in patients with high titers of LMP2-specific
responses, with disease control in approximately 50% of
patients. With the aim to potentiate in vivo T-cell expan-
sion, lymphodepletion was employed before high-dose
EBV-specific CTLs in eleven EBV-related NPC, but results
were comparable [38]. These preliminary data constituted
the ground for an ongoing preclinical study, presented
by Comoli, on the production and expansion of
LMP2-specific CTL from NPC patients. The conven-
tional procedure of cellular activation is modified by
means of LMP2 peptide (15aa) mix. The cell lines
obtained by this protocol were successfully used in the
treatment of a pediatric patient with refractory NPC.
Future studies will attempt to optimize the generation
of LMP2-specific CTL in order to increase the rate of
T-cells specific for the antigens present on NPC. An
important future perspective will be to employ cell
therapy in early phases of disease, within a wider proto-
col, as part of first line treatment or to prevent tumor
recurrence in the adjuvant setting.
Solid tumors in HIV patients
Contributions of the last section were focused on HIV-
associated solid tumors. WHO estimates 33.3 million of
adults and children infected with HIV in the world,
about 820,000 in Europe. In the HAART era, HIV-
infected patients survive to older ages, with prolonged
exposure to cancer risk factors and, nowadays, non-
AIDS Defining Cancers (NADC) represent a much lar-
ger fraction of the overall cancer burden. NADC are
constituted mainly by Hodgkin’s lymphoma and some
solid tumors (lung carcinoma, hepatocarcinoma, GE tu-
mors, head and neck, and anal cancers, skin non melano-
ma cancers, in decreasing order of frequency) associated
with alcohol and smoke exposure, immunedepression,
and viral infection (HCV, HPV, HHV-8, MCPyV).
Emanuela Vaccher (CRO National Cancer Institute,
Aviano, Italy) analyzed data of a recent record-linkage
study between the Italian AIDS registry and the Italian
cancer registries [39,40]. This study allowed to obtain the
standardized incidence ratio (excess risk compared to a
general population matched for age and sex, SIR) of can-
cer in 21,951 AIDS cases reported in Italy between 1986
and 2005, before and after the introduction of HAART.
Results showed interesting changes in the cancer pattern
after the introduction of HAART in 1996. SIR for Kaposi
sarcoma (KS) and non-Hodgkin lymphoma greatly de-
creased in post-HAART era (although the risk for these
cancers remains substantially higher for HIV patients),
whereas SIR for invasive cervical cancer, an AIDS definingcancer, were substantially stable, at high levels, in the two
periods analyzed. From analysis of the epidemiological
data, it is clear that the risk for most NADC were already
high in the pre-HAART, with no significant increase in
the HAART period, except for HCC (SIR = 6.4) [39]. By
analysis of the overall Incidence Rate Ratio (IRR), no sig-
nificant differences in NADCs emerged after the HAART
introduction [40]. Data showed that HCC and lung cancer
were the only tumors with increased incidence in the last
years in Italy (4.6 and 1.8 times, respectively). An interes-
ting data to investigate further is the impact of aging in
the risk of NADCs development of HIV-infected people.
Age-specific incidence rates for NADCs in AIDS patients
were higher than the corresponding curve in the general
population below 45 years of age in pre-HAART and
below 55 years of age in HAART era. The analyses of 595
HD cases and 550 solid tumors cases in the CRO-GICAT
data base (06/2010) indicated that the major characteris-
tics of HIV-infected patients with solid non-AIDS defining
malignancies, compared to the general population were:
middle-age groups, more advanced disease stages III-IV
(49-93%), and poorer prognosis. National guidelines about
HAART administration and diagnostic/clinical approach
of HIV-1 patients, introduced some important concepts:
NADC patients must be treated with chemotherapy and
HAART independently by CD4 count and HIV-RNA;
antineoplastic therapy has only support finality in patients
without HIV therapeutic chance.
Attention was then focused on HCC and HIV. HCC is
an increasing cause of mortality in HIV-infected patients
in the HAART era; the risk of HCC is increased in HIV
patients (SIR = 3-19). Furthermore, HIV is able to acce-
lerate the evolution process of fibrosis/cirrhosis. In the
Italian cohort, 1 year survival of 28% in HIV-positive pa-
tients versus a survival of 76.2% in HIV-negative patients
has been reported. Antonello Malfitano (Fondazione
IRCCS Policlinico “San Matteo”, Pavia, Italy), presented
some contributions that explain the main features, clinical
presentation and outcome of HCC in HIV-infected
patients. The first study presented [41] was based on 41
HIV/HCC patients, that were identified from the GICAT
case series in the period 1995–1998. Results showed that
in HIV-infected patients liver disease was significantly
more advanced at presentation, with higher prevalence of
multifocal and infiltrating lesions. Only three variables
were significantly more frequent in HIV-positive patients
compared with uninfected patients: a higher rate of
chronic hepatitis C, a lower prevalence of heavy alcohol
intake and a higher frequency of infiltrating lesions and
metastasis at first HCC diagnosis. Further aspects to be
highlighted were the shorter interval between the esti-
mated date of first HCV exposure and first diagnosis, and
the younger age of HIV-positive patients (median age at
first diagnosis, 42 years) compared with HIV-negative
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be more rapid in HIV/HCV-coinfected patients, and an
increasing number of cases should be expected in the next
few years. A most recent multicenter observational retros-
pective comparison of 104 HIV/HCC patients and 484
uninfected HCC patients over 13-year period, 1997–2010,
was reported [42]. Results of this study confirmed a signi-
ficantly shorter survival time in HIV-positive HCC pa-
tients, despite better Barcelona Clinic Liver Cancer (BCLC)
stage at diagnosis and a similar therapeutic option rate.
Last contribution was focused on AIDS-Kaposi’s sar-
coma (AIDS-KS). AIDS-KS is the most aggressive form of
KS, and Kaposi’s sarcoma herpesvirus (KSHV, also named
human herpesvirus 8, HHV-8) is the infectious agent
associated with this neoplasia. AIDS-KS most frequently
manifests in a multifocal mucocutaneous distribution in-
volving the face, trunk, genitalia, and/or lower extremities.
Visceral sites most commonly include the lung and gas-
trointestinal tract. KS predictive factors are immune sys-
tem impairment, current CD4+ cell count, current viral
load, and absence of combination antiretroviral therapy
(cART) [43]. KS risk increases as the CD4+ cell count fell,
and is associated with high viral load. HAART is the main-
stay of AIDS-KS treatment; other therapeutic approaches
can be local (radiation, surgical), interferons, and chemo-
therapy. Renato Maserati (Fondazione IRCCS Policlinico
“San Matteo”, Pavia, Italy), presented some studies [44,45]
focused on various aspects of HAART therapy, demonstrat-
ing that HAART therapy was successful over a prolonged
follow-up, well-tolerated and effective approach for KS.
Co-administration of protease inhibitors with antica-
ncer drugs in the management of HIV-related malignan-
cies can cause potential drug-drug interactions. A study
[46] conducted at the CRO-National Cancer Institute-
Aviano, investigated the effect of lopinavir/ritonavir (LPV/
RTV) on the pharmacokinetics of irinotecan (CPT11).
Implications of this study were that the exposure to
CPT11 was altered in patients under HAART regimens,
including LPV/RTV (and potentially other protease inhi-
bitors with enzyme inhibitory properties).
Although KS treatment is based on HAART, in rare
cases individuals may experience KS flare during immune
reconstitution inflammatory syndrome (IRIS), a heteroge-
neous and sometimes fatal disorder of immune perturba-
tion after initiation of highly active antiretroviral therapy.
Such a flare does not necessarily indicate a poor prog-
nosis. Maserati reported a study [47] based on 9 HIV-
infected patients with KS flare after virologic and im-
munologic response to HAART, and 10 cases identified by
computerized search of the medical literature. Systemic
chemotherapy, administered in 10 of 19 cases, led to tu-
mor regression. Even for those patients with rapidly symp-
tomatic KS, early systemic chemotherapy was effective in
suppressing IRIS-associated flare.The Italian group on viral oncology of solid
tumors
The long standing interest and expertise on viral onco-
logy of the several Italian groups participating at the
Pavia meeting prompted the organizers to propose a mul-
tidisciplinary scientific association with the primary aim to
potentiate collaboration throughout the country on basic
research, epidemiology, translational and clinical studies
on viruses and solid cancer. At the end of the meeting,
speakers held a round table discussing these points and
expressed intent to participate as investigators at the pro-
posed association.
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